It is reasonable that future studies consider agents/approaches that activate the ANG‒ribosome biogenesis pathway as a therapeutic schema for pediatric osteoporosis or osteonecrosis, especially for patients receiving long-term GC treatment. This evidence concerns the gene ANG and osteonecrosis.